Compare HTOO & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | HTOO | PPCB |
|---|---|---|
| Founded | 2020 | 2007 |
| Country | Ireland | Australia |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | |
| Sector | Utilities | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0M | 5.7M |
| IPO Year | N/A | N/A |
| Metric | HTOO | PPCB |
|---|---|---|
| Price | $3.39 | $0.19 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 33.8K | ★ 2.9M |
| Earning Date | 02-28-2023 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,024,662.00 | N/A |
| Revenue This Year | $4,832.46 | N/A |
| Revenue Next Year | $81.82 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 105.98 | N/A |
| 52 Week Low | $2.92 | $0.16 |
| 52 Week High | $19.18 | $11.00 |
| Indicator | HTOO | PPCB |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Fusion Fuel Green PLC is a provider of full-service energy engineering and advisory solutions, specializing in green hydrogen and industrial gas applications. It offers a broad portfolio of services, including the design, supply, installation, and maintenance of energy systems, as well as the transport and distribution of liquefied petroleum gas. The company serves a diverse customer base spanning commercial buildings, mixed-use developments, heavy industries, and food service sectors. The group currently derives revenue by providing comprehensive solutions for the liquefied petroleum gas (LPG) industry, which includes the supply, installation, and maintenance of LPG systems, as well as transportation and delivery of LPG in both bulk and cylinder formats.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.